Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

NCT00242918 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: docetaxel
DRUG: ZD1839

Sponsor

Benaroya Research Institute

Collaborators

[object Object]
[object Object]